BACKGROUND AND PURPOSE: Evidence from animal models and examination of human epilepsy surgery specimens indicates that inflammation plays an important role in epilepsy. Positron emission tomography (PET) using [C11]PK11195, a marker of activated microglia, provides a means to visualize neuroinflammation in vivo in humans. We hypothesize that in patients with active epilepsy, [C11]PK11195 PET (PK-PET) may be able to identify areas of focally increased inflammation corresponding to the seizure onset zone. METHODS: A young woman with intractable epilepsy underwent PK-PET as part of an approved research study. PK-PET results were compared with results from other clinical studies. RESULTS: PK-PET revealed an area of focally increased radiotracer uptake in the right frontal lobe corresponding to this patient's seizure focus as identified by ictal and interictal 18F-fluorodeoxyglucose (FDG)-PET and EEG. Routine brain magnetic resonance imaging (MRI) was initially considered normal, though high-resolution studies showed possible subtle dysplasia of the right frontal lobe. The patient underwent a right frontal lobe resection, and pathological evaluation showed focal cortical dysplasia with activated microglia. CONCLUSIONS: PK-PET can identify neuroinflammation associated with subtle focal cortical dysplasia, and may therefore have a clinical role in guiding epilepsy surgery for patients with difficult-to-localize seizure foci.
BACKGROUND AND PURPOSE: Evidence from animal models and examination of humanepilepsy surgery specimens indicates that inflammation plays an important role in epilepsy. Positron emission tomography (PET) using [C11]PK11195, a marker of activated microglia, provides a means to visualize neuroinflammation in vivo in humans. We hypothesize that in patients with active epilepsy, [C11]PK11195 PET (PK-PET) may be able to identify areas of focally increased inflammation corresponding to the seizure onset zone. METHODS: A young woman with intractable epilepsy underwent PK-PET as part of an approved research study. PK-PET results were compared with results from other clinical studies. RESULTS: PK-PET revealed an area of focally increased radiotracer uptake in the right frontal lobe corresponding to this patient's seizure focus as identified by ictal and interictal 18F-fluorodeoxyglucose (FDG)-PET and EEG. Routine brain magnetic resonance imaging (MRI) was initially considered normal, though high-resolution studies showed possible subtle dysplasia of the right frontal lobe. The patient underwent a right frontal lobe resection, and pathological evaluation showed focal cortical dysplasia with activated microglia. CONCLUSIONS: PK-PET can identify neuroinflammation associated with subtle focal cortical dysplasia, and may therefore have a clinical role in guiding epilepsy surgery for patients with difficult-to-localize seizure foci.
Authors: R B Banati; G W Goerres; R Myers; R N Gunn; F E Turkheimer; G W Kreutzberg; D J Brooks; T Jones; J S Duncan Journal: Neurology Date: 1999-12-10 Impact factor: 9.910
Authors: Jason T Lerner; Noriko Salamon; Jason S Hauptman; Tonicarlo R Velasco; Marta Hemb; Joyce Y Wu; Raman Sankar; W Donald Shields; Jerome Engel; Itzhak Fried; Carlos Cepeda; Veronique M Andre; Michael S Levine; Hajime Miyata; William H Yong; Harry V Vinters; Gary W Mathern Journal: Epilepsia Date: 2009-01-21 Impact factor: 5.864
Authors: A Palmini; A Gambardella; F Andermann; F Dubeau; J C da Costa; A Olivier; D Tampieri; P Gloor; F Quesney; E Andermann Journal: Ann Neurol Date: 1995-04 Impact factor: 10.422
Authors: Leah P Dickstein; Jeih-San Liow; Alison Austermuehle; Sami Zoghbi; Sara K Inati; Kareem Zaghloul; Paolo Zanotti-Fregonara; William H Theodore Journal: Epilepsia Date: 2019-05-30 Impact factor: 5.864
Authors: Leah D Gershen; Paolo Zanotti-Fregonara; Irene H Dustin; Jeih-San Liow; Jussi Hirvonen; William C Kreisl; Kimberly J Jenko; Sara K Inati; Masahiro Fujita; Cheryl L Morse; Chad Brouwer; Jinsoo S Hong; Victor W Pike; Sami S Zoghbi; Robert B Innis; William H Theodore Journal: JAMA Neurol Date: 2015-08 Impact factor: 18.302